Industry & Business

AstraZeneca’s blood-thinning drug Brilinta fails clinical trials

 Breaking News
  • Greencore to Divest US Business in $1 Billion Deal Greencore Group, the Irish and UK convenience food business, has agreed to sell its entire US business to an affiliate of Hearthside Food Solutions for US$1.075 billion (£817 million) on a cash and debt-free basis. Hearthside is a major US contract food manufacturer with a heritage in US food industry outsourcing. The disposal will leave [...]...
  • Research and Innovation Critical to Business Success Post Brexit The Managing Director of the Industry Research and Development Group (IRDG) says increased investment in research and innovation by both the business sector and the State is critical in order for Irish businesses to survive the hard hitting impact of Brexit. Denis Hayes says despite budget 2019 proposals State expenditure on research and innovation will [...]...
  • Irish Distillers to Invest €150 Million in Sites in Cork and Dublin Irish Distillers has announced investment of over €150 million in its sites in Cork and Dublin to meet demand for its products as the Irish whiskey renaissance continues apace. This is accelerated by the continued growth of the company’s flagship Jameson brand, which is now in double or triple-digit growth in more than 80 markets [...]...
  • CM Precision Components Opens New Purpose-built Factory in Downpatrick Downpatrick-based CM Precision Components Ltd has officially opened its new 16,000 sq ft manufacturing facility at Invest Northern Ireland’s Killough Road Industrial Estate. The advanced engineering firm has invested almost £1 million in the construction project, to expand its production capabilities and meet the growing demands of its customers. CM Precision Components produces precision machined components for [...]...
  • Arkphire Secures New Investment IT solutions and networking company, Arkphire, has announced that Bregal Milestone, a private capital firm, has completed an investment into the business. The investment by Bregal Milestone comes from their new €400 million pan-European fund dedicated to investing in high-growth European companies. Typical commitments from Bregal Milestone range from €20 million to €60 million. Arkphire provides [...]...

AstraZeneca’s blood-thinning drug Brilinta fails clinical trials

March 23
09:48 2016

clinic-doctor-health-hospital-mediumAstraZeneca Plc has said today that its blood-thinning drug Brilinta failed to help stroke patients as hoped in a major clinical trial. Brilinta didn’t outperform aspirin in the three-month long test on patients with stroke, dealing a blow to a product viewed as an important driver of future sales and profits.

In a clinical trial dubbed Socrates, Brilinta taken twice daily was compared to a once- daily dose of aspirin in patients with two forms of stroke. Those taking the drug had fewer heart attacks, other stroke or death.

While AstraZeneca said “fewer events” were observed in the patients taking Brilinta, the overall trend from the trial did not reach “statistical significance”.

While this latest trial will not affect the current usage of Brilinta, which accounted for 2.5 per cent of AstraZeneca’s total revenues last year, the results will likely come as a blow to the group as it tries to find alternative sources of income to make up for the loss of market exclusivity in the US this year for its best-selling drug Crestor, an anti-cholesterol statin.

Chief Executive Officer Pascal Soriot has identified Brilinta as critical to reaching $45 billion in annual revenue by 2023, a goal set in 2014 as AstraZeneca fended off a takeover attempt by Pfizer Inc. The anti-clotting medicine is sold as a treatment after heart attacks, but AstraZeneca is conducting studies intended to expand the population of patients who can take the pill.

The full results of the trial will be presented at a medical conference on stroke.

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4